维泰瑞隆宣布其SARM1抑制剂SIR2501相关摘要获选2026年美国临床肿瘤学会（ASCO）年会海报展示

2026年4月22日
了解更多
Demyelination of Neurons in Demyelinating Diseases Impact of Mye
2026年3月26日

维泰瑞隆宣布委任王舒展先生为董事会董事

了解更多
2026年3月20日

维泰瑞隆宣布即将展示关于NAMPT激活研究的海报

了解更多
2026年2月6日

员工分享他们在维泰瑞隆的成就与自豪

了解更多
了解更多

科研发表

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

Clin Transl Sci., 2025

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Clin Transl Sci., 2024

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

International Neurology & Brain Disorders Conference, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Journal of Intensive Medicine, 2024